In vitro functional characteristics of dopamine D2 receptor partial agonists in second and third messenger-based assays of cloned human dopamine D2Long receptor signalling

Journal of Psychopharmacology

Volumn 21, Issue 6, 2007, Pages 620-627

  Jordan, Shaun ^a,d   Regardie, Karen ^a   Johnson, Janelle L ^a   Ruoyan Chen, ^a   Kambayashi, Junichi ^a   McQuade, Robert ^b   Kitagawa, Hisashi ^c   Tadori, Yoshihiro ^c   Kikuchi, Tetsuro ^c  

^a OTSUKA PHARMACEUTICAL DEVELOPMENT AND COMMERCIALIZATION INC   (United States)

^b Otsuka Abilify Unit   (United States)

^c OTSUKA PHARMACEUTICAL CO LTD   (Japan)

^d NONE   (United States)

Author keywords

Aripiprazole (OPC 14597); Confocal; Dopamine; Partial agonist; Schizophrenia

Indexed keywords

7 [3 [4 (2,3 DIMETHYLPHENYL) 1 PIPERAZINYL]PROPOXY] 2(1H) QUINOLINONE; ARIPIPRAZOLE; CALCIUM ION; CLOZAPINE; DOPAMINE 2 RECEPTOR STIMULATING AGENT; HALOPERIDOL; MITOGEN ACTIVATED PROTEIN KINASE 1; OLANZAPINE; PHOSPHOPROTEIN; PRECLAMOL; QUETIAPINE; RISPERIDONE; TERGURIDE; ZIPRASIDONE;

ANIMAL CELL; ARTICLE; CALCIUM MOBILIZATION; CHO CELL; CONTROLLED STUDY; DOPAMINE RELEASE; DOWNSTREAM PROCESSING; FEMALE; HUMAN; MOLECULAR CLONING; NONHUMAN; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

ANIMALS; ANTIPSYCHOTIC AGENTS; CALCIUM SIGNALING; CHO CELLS; CLONING, MOLECULAR; CRICETINAE; CRICETULUS; DOPAMINE; DOPAMINE AGONISTS; DOPAMINE ANTAGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; HUMANS; IMMUNOBLOTTING; LISURIDE; MAP KINASE SIGNALING SYSTEM; MICROSCOPY, CONFOCAL; MITOGEN-ACTIVATED PROTEIN KINASE 1; PHOSPHORYLATION; PIPERAZINES; PIPERIDINES; QUINOLONES; RACLOPRIDE; RECEPTORS, DOPAMINE D2; SCHIZOPHRENIA; TIME FACTORS; TRANSFECTION;

EID: 34748829113     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881106072090     Document Type: Article

References (45)

1. Baker J.G., Hall I.P., Hill S.J. (2003) Influence of agonist efficacy and receptor phosphorylation on antagonist affinity measurements: differences between second messenger and reporter gene responses. Mol Pharmacol 64: 679 - 688
2. Benkert O., Muller-Siecheneder F., Wetzel H. (1995) Dopamine agonists in schizophrenia: a review. Eur Neuropsychopharmacol 5 (suppl.). 43 - 53
3. Browning J.L., Patel T., Brandt P.C., Young K.A., Holcomb L.A., Hicks P.B. (2005) Clozapine and the mitogen-activated protein kinase signal transduction pathway: implications for antipsychotic actions. Biol Psychiatry 57: 617 - 623
4. Burris K.D., Molski T.F., Xu C., Ryan E., Tottori K., Kikuchi T., Yocca F.D., Molinoff P.B. (2002) Aripiprazole, a novel antipsychotic, is a highaffinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther 302: 381 - 389
5. Byars A., Burris K., Jordan S., Tottori K., Kikuchi T., McQuade R. (2002) Aripiprazole: a dopamine-serotonin system stabilizer. Eur Neuropsychopharmacol 12 (suppl. 3). S290
6. Chen J., Shen C., Meller E. (2002) 5-HT(1A) receptor-mediated regulation of mitogen-activated protein kinase phosphorylation in rat brain. Eur J Pharmacol 452: 155 - 162
7. Choi E.Y., Jeong D.W., Park K.W., Baik J.H. (1999) G protein-mediated mitogen-activated protein kinase activation by two dopamine D2 receptors. Biochem Biophys Res Commun 256: 33 - 40
8. Clark D., Hjorth S., Carlsson A. (1985 a) Dopamine receptor agonists: mechanisms underlying autoreceptor selectivity. II. Theoretical considerations. J Neural Transm 62: 171 - 207
9. Clark D., Hjorth S., Carlsson A. (1985 b) Dopamine-receptor agonists: mechanisms underlying autoreceptor selectivity. I. Review of the evidence. J Neural Transm 62: 1 - 52
10. Cosi C., Waget A., Rollet K., Tesori V., Newman-Tancredi A. (2005) Clozapine, ziprasidone and aripiprazole but not haloperidol protect against kainic acid-induced lesion of the striatum in mice, in vivo: role of 5-HT(1A) receptor activation. Brain Res 1043: 32 - 41
11. Cussac D., Duqueyroix D., Newman-Tancredi A., Millan M.J. (2002) Stimulation by antipsychotic agents of mitogen-activated protein kinase (MAPK) coupled to cloned, human (h) serotonin (5-HT)(1A) receptors. Psychopharmacology 162: 168 - 177
12. Dean B., Scarr E. (2004) Antipsychotic drugs: evolving mechanisms of action with improved therapeutic benefits. Curr Drug Targets CNS Neurol Disord 3: 217 - 225
13. Fujikawa M., Nagashima M., Inoue T., Yamada K., Furukawa T. (1996) Partial agonistic effects of OPC-14597, a potential antipsychotic agent, on yawning behavior in rats. Pharmacol Biochem Behav 53: 903 - 909
14. Gnegy M.E. (2000) Ca2+/calmodulin signaling in NMDA-induced synaptic plasticity. Crit Rev Neurobiol 14: 91 - 129
15. Hernandez-Lopez S., Tkatch T., Perez-Garci E., Galarraga E., Bargas J., Hamm H., Surmeier D.J. (2000) D2 dopamine receptors in striatal medium spiny neurons reduce L-type Ca2+ currents and excitability via a novel PLC[beta]1-IP3-calcineurin-signaling cascade. J Neurosci 20: 8987 - 8995
16. Jomphe C., Tiberi M., Trudeau L.E. (2006) Expression of D2 receptor isoforms in cultured neurons reveals equipotent autoreceptor function. Neuropharmacology 50: 595 - 605
17. Jordan S., Koprivica V., Chen R., Tottori K., Kikuchi T., Altar C.A. (2002) The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor. Eur J Pharmacol 441: 137 - 140
18. Jordan S., Koprivica V., Dunn R., Tottori K., Kikuchi T., Altar C.A. (2004 a) In vivo effects of aripiprazole on cortical and striatal dopaminergic and serotonergic function. Eur J Pharmacol 483: 45 - 53
19. Jordan S., Chen R., Johnson J., Regardie K., Whitehead R., Tadori Y., McQuade R., Kikuchi T. (2004 b) Guanosine-5'-O-(3-[35S]thio)-triphosphate binding assays can be insensitive in detecting D2 partial agonist drug activity. Int J Neuropsychopharmacol 7 (suppl. 1). S263
20. Jordan S., Chen R., Fernalld R., Johnson J., Regardie K., Kambayashi J., Tadori Y., Kitagawa H., Kikuchi T. (2006) In vitro biochemical evidence that the psychotomimetics phencyclidine, ketamine and dizocilpine (MK-801) are inactive at cloned human and rat dopamine D(2) receptors. Eur J Pharmacol 540: 53 - 56
21. Kane J.M., Carson W.H., Saha A.R., McQuade R.D., Ingenito G.G., Zimbroff D.L., Ali M.W. (2002) Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry 63: 763 - 771
22. Kikuchi T., Tottori K., Uwahodo Y., Hirose T., Miwa T., Oshiro Y., Morita S. (1995) 7-(4-[4-(2,3-Dichlorophenyl)-1-piperazinyl]butyloxy)-3,4-dihydro- 2(1H)-quinolinone (OPC-14597). a new putative antipsychotic drug with both presynaptic dopamine autoreceptor agonistic activity and postsynaptic D2 receptor antagonistic activity. J Pharmacol Exp Ther 274: 329 - 336
23. Kontkanen O., Toronen P., Lakso M., Wong G., Castren E. (2002) Antipsychotic drug treatment induces differential gene expression in the rat cortex. J Neurochem 83: 1043 - 1053
24. Kyosseva S.V. (2004) Mitogen-activated protein kinase signaling. Int Rev Neurobiol 59: 201 - 220
25. Lahti R.A., Figur L.M., Piercey M.F., Ruppel P.L., Evans D.L. (1992) Intrinsic activity determinations at the dopamine D2 guanine nucleotide-binding protein-coupled receptor: utilization of receptor state binding affinities. Mol Pharmacol 42: 432 - 438
26. Lahti A.C., Weiler M.A., Corey P.K., Lahti R.A., Carlsson A., Tamminga C.A. (1998) Antipsychotic properties of the partial dopamine agonist (-)-3-(3-hydroxyphenyl)-N-n-propylpiperidine(preclamol) in schizophrenia. Biol Psychiatry 43: 2 - 11
27. Lawler C.P., Prioleau C., Lewis M.M., Mak C., Jiang D., Schetz J.A., Gonzalez A.M., Sibley D.R., Mailman R.B. (1999) Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes. Neuropsychopharmacology 20: 612 - 627
28. Lee S.P., So C.H., Rashid A.J., Varghese G., Cheng R., Lanca A.J., O'Dowd B.F., George S.R. (2004) Dopamine D1 and D2 receptor co-activation generates a novel phospholipase C-mediated calcium signal. J Biol Chem 279: 35671 - 35678
29. Lu X.H., Dwyer D.S. (2005) Second-generation antipsychotic drugs, olanzapine, quetiapine, and clozapine enhance neurite outgrowth in PC12 cells via PI3K/AKT, ERK, and pertussis toxin-sensitive pathways. J Mol Neurosci 27: 43 - 64
30. Lu X.H., Bradley R.J., Dwyer D.S. (2004) Olanzapine produces trophic effects in vitro and stimulates phosphorylation of Akt/PKB, ERK1/2, and the mitogen-activated protein kinase p38. Brain Res 1011: 58 - 68
31. Meller E., Bohmaker K., Namba Y., Friedhoff A.J., Goldstein M. (1987) Relationship between receptor occupancy and response at striatal dopamine autoreceptors. Mol Pharmacol 31: 592 - 598
32. Meltzer H.Y., Stahl S.M. (1976) The dopamine hypothesis of schizophrenia: a review. Schizophr Bull 2: 19 - 86
33. Neve K.A., Seamans J.K., Trantham-Davidson H. (2004) Dopamine receptor signaling. J Recept Signal Transduct Res 24: 165 - 205
34. Pliska V. (1999) Partial agonism: mechanisms based on ligand-receptor interactions and on stimulus-response coupling. J Recept Signal Transduct Res 19: 597 - 629
35. Pozzi L., Hakansson K., Usiello A., Borgkvist A., Lindskog M., Greengard P., Fisone G. (2003) Opposite regulation by typical and atypical antipsychotics of ERK1/2, CREB and Elk-1 phosphorylation in mouse dorsal striatum. J Neurochem 86: 451 - 459
36. Reynolds G.P. (2004) Receptor mechanisms in the treatment of schizophrenia. J Psychopharmacol 18: 340 - 345
37. Richelson E., Souder T. (2000) Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci 68: 29 - 39
38. Shapiro D.A., Renock S., Arrington E., Chiodo L.A., Liu L.X., Sibley D.R., Roth B.L., Mailman R. (2003) Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology 28: 1400 - 1411
39. Sweatt J.D. (2001) The neuronal MAP kinase cascade: a biochemical signal integration system subserving synaptic plasticity and memory. J Neurochem 76: 1 - 10
40. Tadori Y., Miwa T., Tottori K., Burris K.D., Stark A., Mori T., Kikuchi T. (2005) Aripiprazole's low intrinsic activities at human dopamine D2L and D2S receptors render it a unique antipsychotic. Eur J Pharmacol 515: 10 - 19
41. Takeuchi Y., Fukunaga K. (2003) Differential regulation of NF-kappaB, SRE and CRE by dopamine D1 and D2 receptors in transfected NG108-15 cells. J Neurochem 85: 729 - 739
42. Tamminga C.A. (2002) Partial dopamine agonists in the treatment of psychosis. J Neural Transm 109: 411 - 420
43. Vanhoose A.M., Emery M., Jimenez L., Winder D.G. (2002) ERK activation by G-protein-coupled receptors in mouse brain is receptor identityspecific. J Biol Chem 277: 9049 - 9053
44. Yan Z., Feng J., Fienberg A.A., Greengard P. (1999) D(2) dopamine receptors induce mitogen-activated protein kinase and cAMP response element-binding protein phosphorylation in neurons. Proc Natl Acad Sci USA 96: 11607 - 11612
45. Yokoo H., Goldstein M., Meller E. (1988) Receptor reserve at striatal dopamine receptors modulating the release of [3H]dopamine. Eur J Pharmacol 155: 323 - 327